SCHEMBL3540151

SCHEMBL3540151

CCOC1=C2C=NC=C[N+]2(Cl)C(c2cccc(OCc3ccccc3)c2)=N1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 2/20 0.38
LIPC P11150 1/20 0.38
ACHE P22303 1/20 0.38
LIPE Q05469 1/20 0.38
MAOB P27338 4/20 0.38
NR1H2 P55055 1/20 0.37
MRGPRX4 Q96LA9 1/20 0.37
JAK2 O60674 1/20 0.37
JAK3 P52333 1/20 0.37
FFAR1 O14842 1/20 0.37
PPARD Q03181 1/20 0.37
CYP4F2 P78329 1/20 0.36
CYP4A11 Q02928 1/20 0.36
ERN1 O75460 1/20 0.36
NR4A2 P43354 2/20 0.36
BACE1 P56817 1/20 0.35
ALDH1A1 P00352 1/20 0.35
HPGD P15428 1/20 0.35
XBP1 P17861 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3535621 0.87 MAOB (0.38) BCHELIPCACHELIPEMAOB
SCHEMBL2456978 0.86 MRGPRX4 (0.40) BCHEMAOBNR1H2MRGPRX4CYP4F2
SCHEMBL2460381 0.85 MAOB (0.38) MAOBNR1H2MRGPRX4CYP4F2CYP4A11
SCHEMBL3537188 0.84 JAK2 (0.45) MAOBMRGPRX4JAK2JAK3NR4A2
SCHEMBL2460371 0.84 NR1H2 (0.42) MAOBNR1H2MRGPRX4CYP4F2CYP4A11
SCHEMBL2460621 0.83 NR1H2 (0.39) NR1H2MRGPRX4PPARDCYP4F2CYP4A11
SCHEMBL2459986 0.82 TSHR (0.39) MAOBNR1H2MRGPRX4CYP4F2CYP4A11
SCHEMBL2461277 0.81 ALOX5 (0.40) NR1H2MRGPRX4CYP4F2CYP4A11BACE1
SCHEMBL2458350 0.81 MRGPRX4 (0.38) MAOBNR1H2MRGPRX4CYP4F2CYP4A11
SCHEMBL2460301 0.80 IGF1R (0.35) MAOBNR1H2JAK2ERN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1957496-B1 BICYCLIC PROTEIN KINASE INHIBITORS OSI PHARM INC (US) 2012-10-24 EP disclosed
US-7648987-B2 Bicyclic protein kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2010-01-19 US disclosed
EP-1957496-A2 BICYCLIC PROTEIN KINASE INHIBITORS OSI Pharmaceuticals, Inc. (US) 2008-08-20 EP disclosed
US-20070149521-A1 Bicyclic protein kinase inhibitors OSI PHARMACEUTICALS, INC. 2007-06-28 US disclosed
WO-2007064993-A2 BICYCLIC PROTEIN KINASE INHIBITORS OSI PHARMACEUTICALS, INC. (US) 2007-06-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149521-A1 Bicyclic protein kinase inhibitors CDK1, MAP4K2, MAP4K3 BCHE 1825/4885LIPC 4409/4885ACHE 1849/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.